Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

1.63.       Joint Patents” means all Patents within the Joint Program IP.

 

1.64.       Knowledge” means the actual knowledge after performing a diligent investigation with respect to such facts and information of Chief Executive Officer or Chief Scientific Officer of a Party or any personnel holding positions equivalent to such job titles.

 

1.65.       Licensed Compounds” means [*****].

 

1.66.       Licensed Party” means (i) with respect to the licenses granted in Section 2.1, Lilly and (ii) with respect to the license granted in the proviso to Section 12.4.1(ii), ACI.

 

1.67.       Licensed Product” means any pharmaceutical product that is comprised of or contains [*****].

 

1.68.       Lilly Compound” means [*****].

 

1.69.       Lilly Development Costs” means, with respect to a Licensed Compound or Licensed Product, [*****].

 

1.70.       Lilly Grantback Know-How” means, as used in connection with any grant back license provided in Article 12, all [*****].

 

1.71.       Lilly Grantback Patent Rights” means, as used in connection with any grant back license provided in Article 12, all Patents that [*****].

 

1.72.       Lilly Know-How” means all [*****].

 

1.73.       Lilly Patents” means all of the Patents [*****].

 

1.74.       Major Pharmaceutical Company” means a company that, together with its Affiliates, on a worldwide basis, [*****].

 

1.75.       Manufacture” and “Manufacturing” means with respect to any compound or product, all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of such compound or product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.

 

 10


© AC Immune 2015